Worldwide genetic testing rates are low for patients with prostate cancer
Cost was the most commonly reported barrier to genetic testing.
Related Articles
Multi-dose treatment with 67Cu-SAR-bisPSMA in mCRPC shows promise
“This was a very special moment, delivering the news to this patient that his cancer is now undetectable following the treatment with 2 doses of…
Licensing agreement reached for contrast agent for use in patients with prostate cancer
A late phase 3 trial evaluating the agent is underway at several clinics in Europe.
Grant awarded to aid development of allogeneic CAR T treatment for RCC
“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer…
Dr. Shakuri-Rad highlights the connectivity of the da Vinci 5
“It’s a system that is still not being used to its maximum capability, which is exciting. That means we can continue evolving,” says Jaschar Shakuri-Rad,…
First patient dosed with TLX250-CDx for ccRCC in Australia
The first patient was treated with TLX250-CDx at the Olivia Newton-John Cancer Wellness Centre at Austin Health in Melbourne, Australia,
The emotional toll of surgical complications on urologic surgeons
“It is important as a field that we recognize the potential emotional impact of surgical adverse events,” writes Amy N. Luckenbaugh, MD.
EMA recommends approval of vibegron for OAB
Following the positive recommendation, the European Commission will now review the application for vibegron for potential approval in the OAB setting in all EU member…
Dr. Neil Baum’s 10 tips for being on time as a physician
“There are opportunities for doctors to become more productive, to see more patients, and to avoid the erosion of their incomes,” writes Neil Baum, MD.
Study launches of CAR T therapy for bone metastatic prostate cancer
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective…
2024 AUA Annual Meeting Previews
Video interviews of experts in the field reviewing research being presented at the 2024 AUA Annual Meeting.